VERU Stock Analysis: Buy, Sell, or Hold?
VERU - Veru Inc.
$2.09
-0.17 (-7.52%)
▼
5d:
-8.33%
30d:
-13.99%
90d:
-6.7%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
VERU is down 3.4% this week, but smart money is accumulating calls. Top strike: $3 2026-06-05 with 1 OI. Call ratio: 100% View Scanner →
Strength: 6.7/10
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VERU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VERU shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $2.09, which is considered oversold relative to its 30-day fair value range of $2.23 to $2.44.
Technical Outlook: Technically, VERU is in a downtrend. The price is currently testing key support at $2.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: VERU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $25.00 (+1096.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VERU is in a downtrend. The price is currently testing key support at $2.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: VERU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $25.00 (+1096.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.23 -
$2.44
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 1096.2% below Wall St target ($25.00)
- CAUTION: Recommendation downgraded due to -8.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.23 -
$2.44
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.52
(25.0%)
Support & Resistance Levels
Support Level
$2.19
Resistance Level
$2.35
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.74
Wall Street Target
$25.00
(+1096.2%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: May 15, 2026 2:42 AM ET
Data refreshes hourly during market hours. Next update: 3:42 AM
Data refreshes hourly during market hours. Next update: 3:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 60 BUY |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 54 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$181 | 59 HOLD |
|
VYGR
Voyager Therapeutics Inc |
STRONG BUY
12 analysts |
$15 | 58 HOLD |
